07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Biomics Biotechnologies, Benitec deal

Benitec purchased Biomics’ share in DNA-directed RNAi (ddRNAi)-based HBV drug candidate Hepbarna , which the companies had been developing under a JV. Benitec now has exclusive, worldwide rights to develop and commercialize the preclinical product....